Cargando…

Phenotype distribution of the paraoxonase gene in patients with cardiac disease

INTRODUCTION: Paraoxonase (PON1) is an enigmatic enzyme with multiple enzymatic properties including arylesterase and lactonase activities besides its ability to hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was to determine the phenotype distribution of PON1 in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellidag, Hamit Yasar, Aydin, Ozgur, Eren, Esin, Yilmaz, Necat, Gencpinar, Tugra, Kucukseymen, Selcuk, Yilmaz, Akar, Arslan Ince, Fatma Demet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510503/
https://www.ncbi.nlm.nih.gov/pubmed/28721150
http://dx.doi.org/10.5114/aoms.2016.59674
_version_ 1783250196044447744
author Ellidag, Hamit Yasar
Aydin, Ozgur
Eren, Esin
Yilmaz, Necat
Gencpinar, Tugra
Kucukseymen, Selcuk
Yilmaz, Akar
Arslan Ince, Fatma Demet
author_facet Ellidag, Hamit Yasar
Aydin, Ozgur
Eren, Esin
Yilmaz, Necat
Gencpinar, Tugra
Kucukseymen, Selcuk
Yilmaz, Akar
Arslan Ince, Fatma Demet
author_sort Ellidag, Hamit Yasar
collection PubMed
description INTRODUCTION: Paraoxonase (PON1) is an enigmatic enzyme with multiple enzymatic properties including arylesterase and lactonase activities besides its ability to hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was to determine the phenotype distribution of PON1 in patients with cardiac disease who were classified in coronary artery bypass grafting (CABG), heart valve disease (HVD), heart failure (HF) and ST elevation myocardial infarction (STEMI) groups and healthy subjects as a control group. MATERIAL AND METHODS: A total of 300 people (100 cardiac surgery (70 CABG and 30 HVD), 70 HF, 30 STEMI patients and 100 healthy controls) were admitted to this study. Individual variations in PON1 were determined using the dual substrate (paraoxon and phenylacetate) method. RESULTS: The following phenotype distributions were found in the cardiac disease and control groups: cardiac disease group (n = 200): 48.5% (QQ), 42.5% (QR), 9% (RR) and control group (n = 100): 58% (QQ), 39% (QR), 3% (RR). RR (high activity) phenotypic distribution was more common in the cardiac disease group than in controls (p = 0.04). In particular, the frequency of the RR phenotype was two- to three-fold higher in the STEMI and HF patients compared to the controls as well as CABG and HVD groups. CONCLUSIONS: We found a higher percentage of RR phenotype in STEMI and HF patients compared to a large control group as well as compared to two other groups of cardiac disease patients.
format Online
Article
Text
id pubmed-5510503
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-55105032017-07-18 Phenotype distribution of the paraoxonase gene in patients with cardiac disease Ellidag, Hamit Yasar Aydin, Ozgur Eren, Esin Yilmaz, Necat Gencpinar, Tugra Kucukseymen, Selcuk Yilmaz, Akar Arslan Ince, Fatma Demet Arch Med Sci Clinical Research INTRODUCTION: Paraoxonase (PON1) is an enigmatic enzyme with multiple enzymatic properties including arylesterase and lactonase activities besides its ability to hydrolyze the toxic metabolite of parathion, paraoxon. The aim of this study was to determine the phenotype distribution of PON1 in patients with cardiac disease who were classified in coronary artery bypass grafting (CABG), heart valve disease (HVD), heart failure (HF) and ST elevation myocardial infarction (STEMI) groups and healthy subjects as a control group. MATERIAL AND METHODS: A total of 300 people (100 cardiac surgery (70 CABG and 30 HVD), 70 HF, 30 STEMI patients and 100 healthy controls) were admitted to this study. Individual variations in PON1 were determined using the dual substrate (paraoxon and phenylacetate) method. RESULTS: The following phenotype distributions were found in the cardiac disease and control groups: cardiac disease group (n = 200): 48.5% (QQ), 42.5% (QR), 9% (RR) and control group (n = 100): 58% (QQ), 39% (QR), 3% (RR). RR (high activity) phenotypic distribution was more common in the cardiac disease group than in controls (p = 0.04). In particular, the frequency of the RR phenotype was two- to three-fold higher in the STEMI and HF patients compared to the controls as well as CABG and HVD groups. CONCLUSIONS: We found a higher percentage of RR phenotype in STEMI and HF patients compared to a large control group as well as compared to two other groups of cardiac disease patients. Termedia Publishing House 2016-05-25 2017-06 /pmc/articles/PMC5510503/ /pubmed/28721150 http://dx.doi.org/10.5114/aoms.2016.59674 Text en Copyright: © 2016 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Clinical Research
Ellidag, Hamit Yasar
Aydin, Ozgur
Eren, Esin
Yilmaz, Necat
Gencpinar, Tugra
Kucukseymen, Selcuk
Yilmaz, Akar
Arslan Ince, Fatma Demet
Phenotype distribution of the paraoxonase gene in patients with cardiac disease
title Phenotype distribution of the paraoxonase gene in patients with cardiac disease
title_full Phenotype distribution of the paraoxonase gene in patients with cardiac disease
title_fullStr Phenotype distribution of the paraoxonase gene in patients with cardiac disease
title_full_unstemmed Phenotype distribution of the paraoxonase gene in patients with cardiac disease
title_short Phenotype distribution of the paraoxonase gene in patients with cardiac disease
title_sort phenotype distribution of the paraoxonase gene in patients with cardiac disease
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510503/
https://www.ncbi.nlm.nih.gov/pubmed/28721150
http://dx.doi.org/10.5114/aoms.2016.59674
work_keys_str_mv AT ellidaghamityasar phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease
AT aydinozgur phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease
AT erenesin phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease
AT yilmaznecat phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease
AT gencpinartugra phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease
AT kucukseymenselcuk phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease
AT yilmazakar phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease
AT arslanincefatmademet phenotypedistributionoftheparaoxonasegeneinpatientswithcardiacdisease